Early Data Presented At ASCO Show Potential Of RAD001 To Enhance Efficacy Of, And Overcome Resistance To, Breast Cancer Treatments

Early proof-of-concept studies presented show RAD001 (everolimus) may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments. Findings from a Phase II study show that RAD001 enhances tumor shrinkage when given in combination with letrozole tablets (Femara(R)) to postmenopausal women with newly diagnosed estrogen receptor-positive (ER+) breast cancer.

More: continued here

Filed under: Breast Cancer on June 10th, 2008